This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vermillion Supports First World Ovarian Cancer Day And Effort To Raise Awareness Of The Need For Better Diagnosis And Treatment

AUSTIN, Texas, May 8, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, joins ovarian cancer organizations around the world in recognizing May 8 as World Ovarian Cancer Day

On this day, ovarian cancer organizations are uniting to educate their communities about ovarian cancer and its symptoms. For women living with the disease, and their families and friends, World Ovarian Cancer Day represents a global expression of solidarity in the fight against the disease.

"We commend the organizers of this First World Ovarian Cancer Day for bringing together 26 ovarian cancer organizations across 17 countries to generate greater awareness about this deadly disease," said Thomas McLain, Vermillion's president and chief executive officer. "Given the lethality of ovarian cancer and how often it goes undetected before it's too late, we need to increase public knowledge about its symptoms as well as the critical importance of early and appropriate treatment."

According to, every year ovarian cancer is diagnosed in nearly a quarter of a million women around the world, leading to 140,000 cancer-related deaths. In the U.S., out of the 22,000 women who are diagnosed with ovarian cancer every year, 81% are diagnosed as malignant only after the cancer had spread to other parts of the body (metastases). However, only one in three women with ovarian cancer are initially treated by a gynecologic oncologist, in part due to inadequate diagnostic tests and procedures. These statistics reveal how early detection and proper treatment by a gynecologic oncologist can be the key to survival.

Recent stories in the media have highlighted the deficiencies in the detection and treatment of ovarian cancer, including coverage by the New York Times and NBC Nightly News. According to Dr. Bristow, the director of gynecologic oncology services at UC Irvine Healthcare and principal investigator of the study highlighted in these articles, "If we could just make sure that women get to the people who are trained to take care of them, the impact would be much greater than that of any new chemotherapy drug or biological agent."

Vermillion, which has been dedicated to addressing these deficiencies, has achieved remarkable results with its OVA1® test, the first FDA-cleared test designed to aid in the prediction of malignancy prior to surgery on an ovarian mass. Vermillion developed the OVA1 test together with Johns Hopkins University after nearly a decade of proteomic research. In two published clinical studies, OVA1 demonstrated 96% sensitivity across a broad range of ovarian malignancies and detected over 90% of all early stage ovarian cancers. The studies also reported a 95%-98% negative predictive value, a critical feature for minimizing the likelihood that a non-oncology surgeon discovers ovarian cancer during surgery. The powerful performance of OVA1 helps to ensure that women with ovarian cancer are treated by a gynecologic oncologist, which is a critical determinant of survival.

Since receiving FDA clearance in 2009, Vermillion has worked to increase insurance coverage for the test, as well as greater use by physicians.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs